The safety profile remained consistent, with no new serious side effects reported. Meanwhile, Eisai presented new results on a subcutaneous (under-the-skin) formulation of lecanemab designed for ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

"Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure" was originally created and published by Clinical Trials ...